Ljungman P, Andersson J, Aschan J, Björkstrand B, Hägglund H, Lönnqvist B, Ringdén O, Winiarski J
Department of Medicine, Huddinge University Hospital, Karolinska Institute, Sweden.
Clin Infect Dis. 1996 Jul;23(1):167-9. doi: 10.1093/clinids/23.1.167.
Four allogeneic bone marrow transplant patients who were infected with hepatitis C virus (HCV) before bone marrow transplantation (BMT) were treated with oral ribavirin during and after transplantation. None of the patients had severe liver complications. One patient died early. Polymerase chain reaction analysis revealed that two patients who were HCV RNA-positive before BMT became HCV RNA-negative during therapy and remained HCV RNA-negative during 6 and 12 months of follow-up, respectively. No severe side effects of ribavirin were documented. Ribavirin therapy can be given safely to patients undergoing BMT and can result in clearance of HCV RNA.
4例在骨髓移植（BMT）前感染丙型肝炎病毒（HCV）的异基因骨髓移植患者在移植期间及移植后接受了口服利巴韦林治疗。所有患者均未出现严重肝脏并发症。1例患者早期死亡。聚合酶链反应分析显示，2例在BMT前HCV RNA阳性的患者在治疗期间转为HCV RNA阴性，分别在随访6个月和12个月时仍保持HCV RNA阴性。未记录到利巴韦林的严重副作用。利巴韦林治疗可安全用于接受BMT的患者，并可导致HCV RNA清除。
